Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy (ImmunoPAX)

Universitätsmedizin Mannheim

Status: Completed

Conditions: Immuno-monitoring

Treatments: Other: Immuno-monitoring

Study type: Observational

Funder types: Other

Identifiers

NCT02332642

2014-624N-MA

Details and patient eligibility

About

This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.

Enrollment: 12 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically defined metastatic melanoma patients (AJCC stage IV)
• aged 18 to 80 years
• at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy

Exclusion criteria

• therapy-naive patients
• any contra-indications for (specific) systemic chemotherapy